Switching and withdrawing hormonal agents for castration-resistant prostate cancer.
about
Novel Imidazopyridine Derivatives Possess Anti-Tumor Effect on Human Castration-Resistant Prostate Cancer CellsAnti-Estrogen Withdrawal Effect With Raloxifene? A Case Report.Roles of ubiquitination and SUMOylation on prostate cancer: mechanisms and clinical implications.Alterations in androgen deprivation enhanced prostate-specific membrane antigen (PSMA) expression in prostate cancer cells as a target for diagnostics and therapyFunctional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients.Progress in antiandrogen design targeting hormone binding pocket to circumvent mutation based resistanceNovel mechanism-based therapeutics for androgen axis blockade in castration-resistant prostate cancer.Molecular characterization of a novel androgen receptor transgene responsive to MicroRNA mediated post-transcriptional control exerted via 3'-untranslated region.Topoisomerase 2 Alpha Cooperates with Androgen Receptor to Contribute to Prostate Cancer ProgressionRecent advances in circulating tumor cells and cell-free DNA in metastatic prostate cancer: a review.Clinical relevance of androgen receptor alterations in prostate cancer.Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer.STAT3 and STAT5A are potential therapeutic targets in castration-resistant prostate cancer.Abiraterone acetate withdrawal syndrome: Speculations on the underlying mechanisms.Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide.Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer.
P2860
Q28545928-DFE7DDCC-3A19-4DF0-9AA6-39BD38825F95Q34047152-5FAA691B-467B-42A0-8010-C5E8FD35C7B5Q35380380-19434F02-8696-44AC-AE4B-9D877D1BF273Q36289592-5FECC261-49CE-49E8-9DE8-F6B7684FFD80Q36508759-62E147EF-4779-4C99-AEBE-DA70196AE6E5Q38410885-537E52BE-EA46-4C8C-81F9-CAE7647C7CF3Q38775459-AF4A4B9C-FBE5-46EB-BBBE-AB913547F159Q38785291-7530ECDC-6E9B-496D-8CAD-CECE4826300EQ38820055-45651266-2C24-4B9E-958D-1CE0D3C3EAC5Q39454057-F7992266-9C5C-4496-875A-27BA1F994CB3Q42377108-C4D25D0F-3325-4093-A5DC-6001D6382554Q46086455-3A9D410E-A0F5-445C-8F56-29817EDD0418Q47110097-75155C25-DCA2-41C3-A7D5-D85DAE8E4D68Q50053418-7BB24629-011C-4E26-AEAA-BF5B07B26FDFQ52637922-339D87A6-6BD3-414F-8F07-1437FD51EC69Q53787362-69950A3D-58FA-4158-B6E7-FF3FFEE5A121
P2860
Switching and withdrawing hormonal agents for castration-resistant prostate cancer.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Switching and withdrawing hormonal agents for castration-resistant prostate cancer.
@en
type
label
Switching and withdrawing hormonal agents for castration-resistant prostate cancer.
@en
prefLabel
Switching and withdrawing hormonal agents for castration-resistant prostate cancer.
@en
P2093
P2860
P356
P1476
Switching and withdrawing hormonal agents for castration-resistant prostate cancer
@en
P2093
Alan D Smith
Joaquin Mateo
Johann S de Bono
Roberta Ferraldeschi
Zafeiris Zafeiriou
P2860
P2888
P356
10.1038/NRUROL.2014.345
P407
P577
2015-01-01T00:00:00Z
P6179
1014867744